RxDoctor Payments Data

Tina Bossolono-Williams

Primary Care · Nampa, IDNPI 1891264545

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 25 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by AbbVie at 40.8% of the total. Reporting peaked in 2022 at $201 and has fallen 93.2% since, to $14 in 2024. That places this record below the midpoint for primary care clinicians in ID, where the typical reported total is $390.

$434in general payments, 2019–2025

Across 25 payments — averaging $17.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$177
  • AstraZeneca$69
  • Novo Nordisk$53
  • Hologic Sales And Service, LLC$48
  • Lilly USA, LLC$29
  • Pfizer$18
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$434100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$434 in reported general payments places this provider in the 50th percentile of 48 primary care providers in Idaho.

See all primary care providers in Idaho

Medicare billing

Part B allowed, 2024
$11,187
Medicare patients
91
Services billed
161

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban31$41,583
DilantinPhenytoin Sodium Extended11$3,014
Atorvastatin Calcium172$1,684
Omeprazole110$1,299
Levothyroxine Sodium137$1,299
Tolterodine Tartrate ErTolterodine Tartrate13$973
Albuterol Sulfate HfaAlbuterol Sulfate28$709
Lisinopril88$632
Gabapentin28$578
Fluticasone Propionate28$560
Olmesartan Medoxomil12$555
Losartan Potassium63$519
Metformin Hcl79$509
Pioglitazone Hcl28$504
Duloxetine Hcl19$483

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Dilantin$18$44,59742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 48 primary care providers in Idaho.

Other primary care in Nampa

See the full list for Idaho

Where these figures come from

Is this you, or does something look wrong? →